Biologic therapy for psoriasis reduces incident psoriatic arthritis risk by 46% compared to non-biologic therapy
Biologic Therapy Linked to Lower Risk of Psoriatic Arthritis
This meta-analysis of 124,138 patients found that biologic therapy is associated with a 46% lower risk of developing psoriatic arthritis com…
Biologic therapies, especially IL-23 and IL-17 inhibitors, are linked to a lower risk of developing psoriatic arthritis in adults with psori…
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis
Obesity May Impact How Well Certain Psoriasis Drugs Work
This meta-analysis of 4200 patients found that obesity is associated with lower PASI90 (RR = 0.64), PASI75 (RR = 0.52), and PASI100 (RR = 0.…
New data suggests that patients with obesity may see lower response rates to certain biologic treatments for psoriasis.
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors
Specific Immune Inhibitors Show Varying Risks for Hepatitis B Reactivation
This meta-analysis of 29 studies evaluated the risk of hepatitis B virus reactivation (HBVr) in patients receiving various immunomodulators.…
New analysis shows that certain immune inhibitors like JAK inhibitors may carry a higher risk of hepatitis B reactivation than other drug cl…
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…